These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37012537)

  • 1. Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations.
    Restar A; Minalga BJ; Quilantang MI; Adamson T; Dusic E; van der Merwe LA; Millet G; Rosadiño D; Laguing T; Lett E; Everhart A; Phillips G; Janamnuaysook R; Seekaew P; Baker K; Ashley F; Wickersham J; Wallace SE; Operario D; Gamarel KE
    Curr HIV/AIDS Rep; 2023 Jun; 20(3):160-169. PubMed ID: 37012537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV pre-exposure prophylaxis programme preferences among sexually active HIV-negative transgender and gender diverse adults in the United States: a conjoint analysis.
    Watson DL; Listerud L; Drab RA; Lin WY; Momplaisir FM; Bauermeister JA
    J Int AIDS Soc; 2024 Feb; 27(2):e26211. PubMed ID: 38332521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults.
    Restar A; Wilson-Barthes MG; Dusic E; Operario D; Galárraga O
    Sci Rep; 2024 Oct; 14(1):23482. PubMed ID: 39379446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices.
    Sevelius JM; Deutsch MB; Grant R
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21105. PubMed ID: 27760683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals.
    Klein A; Golub SA
    AIDS Patient Care STDS; 2019 Jun; 33(6):262-269. PubMed ID: 31166785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam.
    Doan AH; Vu CMH; Nguyen TT; Green KE; Phan HTT; Janamnuaysook R; Vu BN; Le TM; Do KQ; Tran TT; Ngo TM; Basu L; Tran LK; Humeau Z
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25996. PubMed ID: 36225133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review.
    Dang M; Scheim AI; Teti M; Quinn KG; Zarwell M; Petroll AE; Horvath KJ; John SA
    AIDS Patient Care STDS; 2022 Jun; 36(6):236-248. PubMed ID: 35687813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis.
    Grant RM; Sevelius JM; Guanira JV; Aguilar JV; Chariyalertsak S; Deutsch MB
    J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 3(Suppl 3):S226-9. PubMed ID: 27429187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women.
    Sevelius JM; Keatley J; Calma N; Arnold E
    Glob Public Health; 2016; 11(7-8):1060-75. PubMed ID: 26963756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies.
    Wilson EC; Turner CM; Arayasirikul S; Lightfoot M; Scheer S; Raymond HF; Liu A
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25539. PubMed ID: 32602642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).
    Cespedes M; Das M; Hojilla JC; Blumenthal J; Mounzer K; Ramgopal M; Hodge T; Torres TS; Peterson C; Shibase S; Elliott A; Demidont AC; Callaghan L; Watson CC; Carter C; Kintu A; Baeten JM; Ogbuagu O
    PLoS One; 2022; 17(6):e0267780. PubMed ID: 35657826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intention to Use Different Formulations of Longer Acting HIV Pre-Exposure Prophylaxis Among Transgender and Gender Expansive Individuals: The Roles of Social Vulnerability and Medical Mistrust.
    Schnarrs PW; Zuñiga J; Benitez G; Fliedner P; Norwood A; Croll M; Oviedo LDS; Buchorn J; Oeffinger J; Lane R; Schelling E; Pham G; Pate T; Arnold EM
    AIDS Patient Care STDS; 2024 Feb; 38(2):51-60. PubMed ID: 38381948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California.
    Watson CW; Pasipanodya E; Savin MJ; Ellorin EE; Corado KC; Flynn RP; Opalo C; Lampley E; Henry BL; Blumenthal J; Bolan R; Morris S; Moore DJ
    AIDS Educ Prev; 2020 Dec; 32(6):472-485. PubMed ID: 33779208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Some of us, we don't know where we're going to be tomorrow." Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco.
    Cahill SR; Keatley J; Wade Taylor S; Sevelius J; Elsesser SA; Geffen SR; Wang T; Mayer KH
    AIDS Care; 2020 May; 32(5):585-593. PubMed ID: 31482726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California.
    Sevelius JM; Glidden DV; Deutsch M; Welborn L; Contreras A; Salinas A; Venegas L; Grant RM
    J Acquir Immune Defic Syndr; 2021 Dec; 88(S1):S27-S38. PubMed ID: 34757990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals.
    Poteat TC; Radix A
    Drugs; 2020 Jul; 80(10):965-972. PubMed ID: 32451925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Exposure Prophylaxis in Trans Populations: Providing Gender-Affirming Prevention for Trans People at High Risk of Acquiring HIV.
    Deutsch MB
    LGBT Health; 2018 Oct; 5(7):387-390. PubMed ID: 30272493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Association Between Gender Affirmation and PrEP use Among Transgender Women in New York City.
    Rivera AV; Lopez JM; Braunstein SL
    AIDS Behav; 2023 May; 27(5):1523-1530. PubMed ID: 36574185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Barriers and Facilitators of Pre-exposure Prophylaxis (PrEP) Among Transgender and Gender Diverse Adults in an Integrated Health Care System.
    Bruxvoort K; Portugal C; Munis M; Pak K; Hechter R
    AIDS Behav; 2023 Aug; 27(8):2579-2591. PubMed ID: 36650390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility.
    Patel N; Blumenthal J; Dubé MP; Hood A; Bolan R; Morris S
    LGBT Health; 2022 Apr; 9(3):199-206. PubMed ID: 35196473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.